Eruptive keratoacanthomas secondary to nivolumab immunotherapy

被引：15
|
作者：
Bednarek, Robert [1 ]
Marks, Katherine [1 ]
Lin, George [2 ]
机构：
[1] Geisinger Med Ctr, Dept Dermatol, Danville, PA 17822 USA
[2] Geisinger Med Ctr, Dept Pathol, Div Dermatopathol, Danville, PA 17822 USA
来源：
INTERNATIONAL JOURNAL OF DERMATOLOGY | 2018年 / 57卷 / 03期
关键词：
THERAPY;
D O I：
10.1111/ijd.13893
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E28 / E29
页数：2
相关论文
共 35 条
  • [21] Pityriasis Rosea-Like Rash Secondary to Intravesical Bacillus Calmette-Guerin Immunotherapy
    Oh, Chee Won
    Yoon, Jimi
    Kim, Chi Yeon
    ANNALS OF DERMATOLOGY, 2012, 24 (03) : 360 - 362
  • [22] Immunotherapy rechallenge after nivolumab treatment in advanced non small cell lung cancer in the real-world setting: A national data base analysis
    Levra, Matteo Giaj
    Cotte, Francois-Emery
    Corre, Romain
    Calvet, Christophe
    Gaudin, Anne-Francoise
    Penrod, John R.
    Grumberg, Valentine
    Jouaneton, Baptiste
    Jolivel, Ronan
    Assie, Jean-Baptiste
    Chouaid, Christos
    LUNG CANCER, 2020, 140 : 99 - 106
  • [23] Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with PTEN mutation: a case report and literature review
    Oh, Youjin
    Park, Joo Hee
    Djunadi, Trie Arni
    Shah, Zunairah
    Chung, Liam Il-Young
    Chae, Young Kwang
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [24] Response assessment in non-small cell lung cancer immunotherapy: initial experiences in utilizing FDG PET/CT and the PD-1 blocker nivolumab
    Kauffmann-Guerrero, Diego
    Schindler, Andreas
    Tufman, Amanda
    Syunyaeva, Zulfiya
    Pfluger, Thomas
    Huber, Rudolf Maria
    Berger, Frank
    Kahnert, Kathrin
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2019, 12 (02) : 149 - 155
  • [25] Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China
    Lin, Ying-tao
    Liu, Tian-xiu
    Chen, Jian
    Wang, Chang
    Chen, Ying
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [26] Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
    Evans, Rachel
    Lee, Kelvin
    Wallace, Paul K.
    Reid, Mary
    Muhitch, Jason
    Dozier, Askia
    Mesa, Circe
    Luaces, Patricia L.
    Santos-Morales, Orestes
    Groman, Adrienne
    Cedeno, Carlos
    Cinquino, Aileen
    Fisher, Daniel T.
    Puzanov, Igor
    Opyrchal, Mateusz
    Fountzilas, Christos
    Dai, Tong
    Ernstoff, Marc
    Attwood, Kristopher
    Hutson, Alan
    Johnson, Candace
    Mazorra, Zaima
    Saavedra, Danay
    Leon, Kalet
    Lage, Agustin
    Crombet, Tania
    Dy, Grace K.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [27] Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
    Cohen, Philip R.
    Kato, Shumei
    Goodman, Aaron M.
    Ikeda, Sadakatsu
    Kurzrock, Razelle
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (08)
  • [28] Clinical outcomes and survival differences between primary, secondary and concomitants carcinoma in situ of urinary bladder treated with BCG immunotherapy
    Piszczek, Radoslaw
    Krajewski, Wojciech
    Malkiewicz, Bartosz
    Krajewski, Piotr
    Tukiendorf, Andrzej
    Zdrojowy, Romuald
    Kolodziej, Anna
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (03) : 1338 - 1344
  • [29] Secondary primary malignancies after treatment with chemo-immunotherapy in treatment-naive patients with CLL: a systematic literature review
    Csanadi, Marcell
    Agh, Tamas
    Tordai, Attila
    Tapprich, Christoph
    Voko, Zoltan
    Stamatopoulos, Kostas
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (03) : 273 - 284
  • [30] Effects of Cancer Immunotherapy Regimens on Primary vs. Secondary Immune Responses and the Potential Impact on Long-Term Antitumor Responses
    Alderson, Kory L.
    Murphy, William J.
    CROSSROADS BETWEEN INNATE AND ADAPTIVE IMMUNITY II, 2009, 633 : 81 - 89
1234